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Background: The purpose of this study was to review the current literature and information 
on the combination product Juvisync™ (sitagliptin + simvastatin), which was approved by the 
US Food and Drug Administration in October 2011.
Methods: PubMed (2001–2014) was searched for primary and review articles on sitagliptin, 
simvastatin, or the combination product. Drug manufacturing data and product labeling were 
also used. Studies of simvastatin, sitagliptin, or the combination were screened and analyzed to 
include relevant and recent papers. Selected English language trials were limited to those with 
human subjects and included both safety and efficacy outcomes.
Results: When compared with glipizide as add-on therapy to metformin, sitagliptin was 
noninferior but had lower rates of hypoglycemia and weight gain. In addition, when compared 
with insulin glargine, sitagliptin was less effective in decreasing glycosylated hemoglobin, 
but was associated with significantly lower rates of hypoglycemia. Further, trials have shown 
a beneficial effect of using statins in patients with diabetes mellitus with regard to decreasing 
cardiovascular risk, regardless of baseline lipid levels or the presence of a cardiac disease. 
Both medications have also demonstrated an acceptable side effect profile. However, caution 
is needed when coadministering with any drug that may increase simvastatin levels to reduce 
the risk of myopathy and rhabdomyolysis.
Conclusion: Juvisync should be used in patients requiring both sitagliptin and simvastatin. 
Both agents have shown good efficacy and acceptable safety profiles. Sitagliptin is a good 
option for diabetic patients to improve glycemic control with a lower risk of hypoglycemia 
and weight gain.
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Introduction
Type 2 diabetes is a chronic metabolic disease characterized by insulin resistance, where 
muscle and adipose cells are not able to respond adequately to normal levels of insulin. 
According to the Centers for Disease Control and Prevention, the number of people 
with type 2 diabetes mellitus (DM) in the USA is now estimated to be 26 million and 
projected to triple by the year 2050.1 Diabetes is known as a “silent killer” since patients 
die more often from chronic complications rather than hyperglycemic crisis if uncon-
trolled. The disease damages the eyes (retinopathy), the kidneys  (nephropathy), and 
the nervous system (neuropathy). It also has macrovascular complications, including 
peripheral vascular disease, cerebrovascular disease (CVD), and coronary heart disease 
(CHD). Therefore, the main goal of diabetes management and control is to minimize 
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and delay its complications. However, there has been debate 
on how much is considered appropriate control. The Ameri-
can Diabetes Association recommends a glycemic target of a 
glycosylated hemoglobin (HbA
1c
) ,7%, while the American 
Association of Clinical Endocrinologists has a stricter goal 
of an HbA
1c
 ,6.5%.2,3 Studies have shown that glycemic 
control in DM slows the progression of microvascular com-
plications.4 Further, in a 10-year follow-up of patients in the 
UK Prospective Diabetes Study, those with a lower glycemic 
target (HbA
1c
 ,7%) had a reduced risk of cardiovascular 
events versus those with a higher target (HbA
1c
 ,7.9%).5 
However, results from the ADVANCE trial that included 
11,140 patients with type 2 diabetes were different. After 
an average of 5 years of follow-up, intensive control (HbA
1c
 
,6.5%) reduced the incidence of combined major macrovas-
cular and microvascular events by 10% (hazards ratio [HR] 
0.9; 95% confidence interval [CI] 0.82–0.98; P=0.01), but 
there was no significant difference in major macrovascular 
events (HR 0.94; 95% CI 0.84–1.06; P=0.32), death from car-
diovascular causes (HR 0.88; 95% CI  0.74–1.04; P=0.12), or 
death from any cause (HR 0.93; 95% CI 0.83–1.06; P=0.28). 
In addition, severe hypoglycemia was more common in 
the intensive control group (HR 1.86; 95% CI 1.42–2.40; 
P,0.001).6 Therefore, the glycemic target should be indi-
vidualized after weighing the microvascular benefits versus 
the risks of hypoglycemia and weight gain.
Sitagliptin, a dipeptidyl peptidase (DPP)-4 inhibitor, 
showed efficacy similar to that of glipizide in a clinical 
trial but had a lower risk of hypoglycemia.7 Vildagliptin, 
another DPP-4 inhibitor, showed efficacy similar to that of 
thiazolidinediones, but without weight gain.8 This has made 
DPP-4 inhibitors promising agents when add-on therapy is 
needed to maximize glycemic control with a lower risk of 
hypoglycemia and weight gain.
Having no proof as yet that glycemic control can sig-
nificantly decrease macrovascular complications, attention 
has been focused on other means of prevention, especially 
given that cardiovascular diseases are considered the major 
cause of morbidity and mortality in DM. Other risk factors 
for CVD such as hypertension and dyslipidemia usually 
coexist with DM. Nevertheless, DM is always considered 
a coronary artery disease risk equivalent. Therefore, the 
target low-density lipoprotein (LDL) cholesterol level in 
diabetic patients is ,100 mg/dL (2.60 mmol/L), and pref-
erably ,70 mg/dL (1.8 mmol/L). Lifestyle modification is 
indicated in all DM patients. In patients with overt CVD or 
who are more than 40 years of age and have other risk factors 
for CVD, statins should be added to lifestyle therapy regard-
less of baseline lipid levels.9–11 Trials have shown a linear 
relationship between LDL cholesterol concentration and rela-
tive CVD risk; thus, any reduction in LDL cholesterol levels 
would have a similar relative reduction in CVD risk.11–14 For 
patients aged 40 years or younger, addition of a statin should 
be considered if LDL cholesterol remains .100 mg/dL and 
in those with several CVD risk factors.9–11
Juvisync™, a medication approved by the US Food and 
Drug Administration (FDA), is a combination of sitagliptin and 
simvastatin in one pill. It was approved in October 2011 and is 
manufactured by MSD International GmbH for Merck and Co.15 
Sitagliptin phosphate monohydrate is described chemically 
as 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-
5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]
pyrazine phosphate (1:1) monohydrate, with the structural 
formula shown in Figure 1.16 Simvastatin is butanoic acid, 
2,2-dimethyl-,1,2,3,7,8,8a-hexahydro- 3,7-dimethyl-8-[2-
(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-
naphthalenyl ester, [1S-[1α,3α,7β,8β (2S*,4S*),-8aβ]], with 
the structural formula shown in Figure 2.16 The combination 
pill is indicated for patients requiring both medications, and 
is considered have significant HbA
1c
-lowering ability and 
cardiovascular benefits as well. The objective of this article 
is to provide an overview of sitagliptin and simvastatin used 
separately and in combination, which led to the development 
of Juvisync.
Methods for selection and 
assessment of the literature
PubMed (2001–2014) was searched for primary literature and 
review articles on sitagliptin, simvastatin, or the  combination. 
Mainly clinical trials about each active ingredient of Juvisync 
and their combination were identified, in addition to reviews, 
meta-analysis, case reports involving each ingredient indi-
vidually or in combination, and guidelines for diabetes and 
lipid-lowering agents. However, we did not find any clinical 
efficacy studies comparing Juvisync with sitagliptin and sim-
vastatin as separate tablets. The search was limited to human 
studies published in the English language and included both 
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Figure 1 Structural formula for sitagliptin.
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of LDL. It decreases not only LDL, but triglycerides, 
intermediate-density lipoprotein, and very-LDL as well, and 
increases high-density lipoprotein.16
Pharmacokinetics
Bioequivalence studies in healthy subjects show that 
Juvisync is bioequivalent to coadministration of sitagliptin 
and simvastatin as separate tablets.19 Important pharmacoki-
netic information on sitagliptin and simvastatin is shown in 
Table 1.16,18,20
Sitagliptin and simvastatin do not have a clinically 
meaningful pharmacokinetic interaction. A randomized, 
open-label, crossover study assessing the effect of sitagliptin 
on the pharmacokinetics of simvastatin showed no statisti-
cally significant difference in the kinetics of simvastatin in 
the combination versus simvastatin alone. Therefore, there 
is no need to adjust the dose of simvastatin when it is coad-
ministered with sitagliptin.21
Clinical trials
Sitagliptin
Several studies have demonstrated the efficacy and safety 
of sitagliptin. In a 24-week study, the efficacy and safety of 
sitagliptin was assessed in 441 patients with type 2 DM who 
were not controlled on glimepiride alone or combined with 
metformin. The primary outcome (change in HbA
1c
 from 
baseline to 24 weeks) was decreased by 0.74% (P,0.001) in 
those who received sitagliptin when compared with placebo. 
In those on the combination of metformin and glimepiride, 
sitagliptin reduced the HbA
1c
 by 0.89% relative to placebo. 
In those on glimepiride alone, sitagliptin decreased HbA
1c
 by 
0.57% relative to placebo. However, sitagliptin did have a 
slightly higher risk of hypoglycemia and weight gain.22 In a 
similar study that assessed the efficacy and safety of combin-
ing sitagliptin with a low-dose sulfonylurea, the change in 
HbA
1c
 was 0.8% (95% CI –0.9 to 0.68, P,0.001).23
Sitagliptin was also compared to glipizide as add-on 
therapy to metformin in uncontrolled patients. In this 
52-week study, 1,172 patients were randomized to  addition of 
 sitagliptin 100 mg daily or glipizide 5 mg daily to  metformin. 
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Figure 2 Structural formula for simvastatin.
Table 1 Pharmacokinetics
Absorption Distribution Metabolism Elimination
Simvastatin Tmax 4 hours 
Bioavailability ,5%
95% bound to  
plasma proteins
Undergoes extensive first-pass 
metabolism in the liver via CYP3A4
60% eliminated in the feces; 13% in the urine; 
27% eliminated through other mechanisms
Sitagliptin Tmax 1–4 hours 
Bioavailability 87%
38% bound to  
plasma proteins
Minimally metabolized via CYP3A4  
and CYP2C8 to inactive metabolites
87% eliminated in the urine (79% as unchanged 
drug, 8% as metabolites); 13% in feces
Abbreviations: Tmax, time to peak plasma concentration; CYP, cytochrome P450.
safety and efficacy outcomes. Manufacturing data and prod-
uct labeling were also used.
Pharmacology
Sitagliptin, a DPP-4 inhibitor, is an oral antidiabetic agent 
that acts by slowing the inactivation of incretin hormones 
such as glucagon-like peptide-1 and glucose-dependent 
insulinotropic polypeptide, thereby increasing their action. 
These hormones are a part of the body’s physiological system 
for glucose homeostasis. Their secretion by the intestines 
is increased in response to elevated blood glucose levels 
following a meal. Glucagon-like peptide-1 and glucose-
dependent insulinotropic polypeptide then act on the pancreas 
to increase synthesis and release of insulin as well as decreas-
ing secretion of glucagon and release of glucose from the 
liver; however, these hormones are rapidly deactivated by the 
DPP-4 enzyme. Thus, by selectively inhibiting this enzyme, 
sitagliptin increases insulin release and decreases that of 
glucagon in a glucose-dependent manner.16–18 this property 
makes sitagliptin unique among the antidiabetic agents.
Simvastatin is a prodrug that is hydrolyzed in the body 
to its active form, β-hydroxyacid. It acts by inhibiting the 
hepatic enzyme HMG-CoA reductase that is required for the 
rate-limiting step in the biosynthesis of cholesterol, leading 
to a decrease in intracellular cholesterol concentrations. The 
liver then compensates by increasing the number of LDL 
receptors on its surface, resulting in increased clearance 
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The results showed that sitagliptin was noninferior to 
 glipizide in reducing HbA
1c
. However, hypoglycemia was 
significantly worse (P,0.001) with glipizide (32%) than 
with sitagliptin (5%). Further, sitagliptin led to weight loss 
versus weight gain with glipizide.7
Sitagliptin was also compared with insulin. EASIE was 
a 6-month study comparing sitagliptin with insulin glargine 
in patients not controlled on metformin. Although the mean 
decrease in HbA
1c
 was greater on insulin glargine (-1.72%) 
than on sitagliptin (-1.13%; P,0.0001), there were sig-
nificantly more hypoglycemic events on insulin glargine 
(4.21 versus 0.5 events per patient-year, P,0.0001).25 In 
another 24-week study, 641 patients with type 2 diabetes were 
randomized to assess the efficacy of sitagliptin as add-on to 
insulin therapy. Sitagliptin provided significant improve-
ments in HbA
1c
 when compared with placebo. However, 
there were more hypoglycemic events in patients treated 
with sitagliptin.16
Simvastatin
In the subgroup analysis of diabetes in the Heart Protection 
Study, patients were randomized to receive either simvastatin 
40 mg daily or placebo. The primary outcome was the first 
post-trial incidence of major coronary events and vascular 
events. The results showed a significant relative risk reduc-
tion for the primary outcome. There was a 20% reduction 
in risk of coronary events and a 37% reduction in nonfatal 
myocardial infarction. Diabetic patients without CHD were 
examined for primary prevention, and the results showed 
a 33% relative risk reduction for major vascular events 
(P=0.0003); the results were not affected by duration of dia-
betes or extent of glycemic control. In addition, the reduction 
in risk of the primary outcome was not affected by baseline 
LDL level. In the subgroup of diabetic patients with baseline 
LDL ,116 mg/dL, the relative risk reduction for major vas-
cular events remained significant (27%, P=0.0007).13,14,26
CARDS is another study that assessed statin use specifi-
cally in type 2 diabetes. It assessed the efficacy of low-dose 
atorvastatin (10 mg daily) for primary prevention of CVD in 
patients with type 2 DM. The primary outcome was a com-
posite of the first occurrence of either an acute CHD event, 
stroke, or coronary revascularization. The primary outcome 
occurred in 5.8% of the atorvastatin group versus 9% of the 
placebo group (HR 0.63; 95% CI 0.48–0.83; P=0.001), with 
a 37% relative risk reduction. Tests for heterogeneity of 
results for baseline lipid levels, HbA
1c
, albuminuria, smok-
ing status, or systolic blood pressure were not significant.12 
Atorvastatin 20 mg daily was also studied in 1,255 patients 
with type 2 DM on hemodialysis. The primary outcome was 
a composite of cardiac death, nonfatal myocardial infarction, 
and stroke. Atorvastatin caused an 8% relative risk reduction 
for the composite outcome; however, this was not statistically 
significant (relative risk 0.92; 95% CI 0.77–1.1; P=0.37). 
This study could not show a significant effect of atorvastatin 
on cardiovascular events in hemodialysis patients.27
In a diabetic subgroup analysis of the LIPID trial, 6 years 
of treatment with pravastatin 40 mg daily led to a 24% rela-
tive risk reduction for CHD (P,0.001).28 A meta-analysis 
of 58 trials showed the highest LDL-lowering ability for 
rosuvastatin 80 mg (60%), followed by atorvastatin 80 mg 
(55%) and simvastatin 40 mg (40%). It also showed that for 
each 1 mmol/L reduction in LDL, the risk of ischemic heart 
disease was decreased by 11% in the 1st year, 24% in the 
2nd year, 33% from the 3rd to 5th year, and 36% thereafter 
(P,0.001).29
Another analysis compared three statins  (atorvastatin, 
simvastatin, and pravastatin) using eight randomized placebo-
controlled trials for long-term cardiovascular  prevention. 
Statistical assessment showed only minor heterogeneity in 
the effect sizes of the trials. The results showed that the three 
statins reduced lipid levels to a similar degree.  Moreover, no 
statistically significant difference was found with regard to 
fatal CHD, nonfatal myocardial infarction, stroke, cardiovas-
cular death, or all-cause mortality.30  However, a large meta-
analysis including 170,255 patients from 76 randomized trials 
assessing the efficacy and safety of statins for cardiovascular 
disease showed an increased risk of new-onset diabetes (odds 
ratio 1.09; 95% CI 1.02–1.17; P=0.001) and 11% of these 
cases were attributed to statin therapy itself (I2=11%).31
In light of this finding, an analysis of the JUPITER trial 
was done to weigh the benefits versus risks of using statins 
for primary prevention. In individuals with one or more risk 
factors for DM (metabolic syndrome, impaired fasting glu-
cose, body mass index .30, HbA
1c
 .6%), rosuvastatin led 
to a 39% reduction in the primary endpoint, ie, composite 
of myocardial infarction, stroke, hospital admission due to 
unstable angina, arterial revascularization, or cardiovascular 
death (HR 0.61; 95% CI 0.47–0.79; P=0⋅0001), a 36% reduc-
tion in risk of venous thromboembolism (HR 0.64; 95% CI 
0.39–1.06; P=0.08), and a 17% reduction in total mortality 
(HR 0.83; 95% CI 0.64–1.07; P=0.15). On the other hand, 
it also led to a 28% increase in diabetes (HR 1.28; 95% CI 
1.07–1.54; P=0.01). For patients with no major risk  factors 
for diabetes, rosuvastatin led to a 52% reduction in the 
primary endpoint (HR 0.48; 95% CI 0.33–0.68; P=0.0001), 
a 53% reduction in venous thromboembolism (HR 0.47; 
Vascular Health and Risk Management 2015:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
129
Combination tablet for type 2 diabetes and hypercholesterolemia
95% CI 0.21–1.03; P=0.05), and a 22% reduction in total 
mortality (HR 0.78; 95% CI 0.59–1.03; P=0.08). However, 
it did not cause any increase in diabetes (HR 0.99; 95% CI 
0.45–2.21; P=0.99). Thus, for patients with pre-existing 
major risk factors for diabetes, for every 54 cases of new-
onset diabetes, a total of 134 vascular events or deaths were 
avoided. As for those with no risk factors for diabetes, a total 
of 86 vascular events or deaths were avoided with no new 
cases of diabetes.32
There have been no clinical efficacy studies comparing 
Juvisync with sitagliptin and simvastatin administered as 
separate tablets, and no ongoing clinical trials with Juvisync 
are currently registered by the FDA.
Contraindications/adverse events/
precautions/drug interactions
Contraindications
Contraindications to the use of Juvisync include any history 
of serious hypersensitivity to sitagliptin or simvastatin, active 
liver disease or any persistent unexplained elevation in liver 
enzymes, and pregnancy and lactation. In addition, Juvisync 
is contraindicated for coadministration with gemfibrozil, 
cyclosporine, danazol, or any strong cytochrome P450 3A4 
inhibitor.16,19
Adverse events
The most common side effects of sitagliptin seen in the 
clinical trials were upper respiratory tract infection, nasophar-
yngitis, and headache. Hypoglycemia was also seen when 
added to insulin or sulfonylureas.16 The most common side 
effects of simvastatin were myalgia, headache, abdominal 
pain, constipation, and nausea.16
Precautions
Post-marketing reports have been published on the incidence 
of acute pancreatitis in patients on sitagliptin.33,34 However, it 
remains unknown whether sitagliptin actually does increase 
the risk of acute pancreatitis. A retrospective cohort study 
of 786,656 patients was performed with the help of a large 
medical and pharmacy claims database. The incidence of 
acute pancreatitis in the nondiabetic control, diabetic con-
trol, exenatide, and sitagliptin groups was 1.9, 5.6, 5.7, and 
5.6 cases, respectively, per 1,000 patient years. The risk 
was significantly higher in the combined diabetic groups 
than in the nondiabetic control group (adjusted HR 2.1; 
95% CI 1.7–2.5). The risk of acute pancreatitis was similar 
in the sitagliptin group versus the diabetic control group 
(HR 1.0; 95% CI 0.7–1.3). Thus, this study did show an 
increased incidence of acute pancreatitis in diabetic patients 
versus nondiabetic patients, but did not find a causal relation-
ship between sitagliptin and acute pancreatitis.35
In addition, a further warning for sitagliptin includes a 
higher risk of hypoglycemia when combined with insulin 
or sulfonylureas.16,22,23 Therefore, adjustment of the dose of 
insulin or sulfonylureas is needed when combining these 
agents with Juvisync.
The main label warnings for simvastatin are the risk of 
myopathy, rhabdomyolysis, and liver enzyme  abnormalities. 
In the SEARCH trial, which compared the safety and effi-
cacy of simvastatin 80 mg versus 20 mg in patients surviv-
ing myocardial infarction, myopathy developed in 0.9% of 
the patients receiving the 80 mg dose versus only 0.03% 
of those receiving the 20 mg dose (relative risk 26.6; 95% 
CI 6.5–109.3; P,0.0001). Rhabdomyolysis developed in 
0.4% at the 80 mg dose and in none at the 20 mg dose.36,37 
Thus, the risk of myopathy and rhabdomyolysis appears to 
be dose-dependent. Although Juvisync does not contain an 
80 mg dose for simvastatin, caution is still warranted.
There has also been a case report of a patient with 
chronic kidney disease who developed acute kidney injury 
and rhabdomyolysis after receiving high doses of sitagliptin 
and simvastatin. The patient was already at home on simvas-
tatin 80 mg daily and ezetimibe 10 mg daily, both of which 
increase the risk of rhabdomyolysis. The patient was started 
on sitagliptin 50 mg 6 weeks prior to presentation and was 
titrated to 100 mg daily 3 weeks later. One week after the dose 
titration, the patient started to have muscle pain in the thighs. 
Upon admission and diagnosis of acute kidney injury and 
rhabdomyolysis, all drugs that could have led to this problem 
were discontinued, including sitagliptin, simvastatin, and 
ezetimibe. The patient’s kidney function recovered in a week, 
and all medications were resumed except the aforementioned 
three drugs. Simvastatin was replaced with lovastatin, with 
no recurrence of rhabdomyolysis.38
Simvastatin, like all other statins, caused elevations in 
liver enzymes (more than three times the upper normal limit) 
in almost 1% of patients who received it in clinical trials.16 
Laboratory testing for liver enzymes is required upon initia-
tion of Juvisync and whenever clinically needed.
As discussed earlier, recent studies have suggested that 
statin use may be linked to occurrence of new-onset diabetes. 
However, analysis of the JUPITER trial showed that this was 
only significant in patients with pre-existing risk factors for 
diabetes, and that the cardioprotective benefits outweigh 
the risk of new-onset diabetes.32 Further, a retrospective 
cohort study including 16,027 patients with hypertension 
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and dyslipidemia showed that those receiving fluvastatin, 
lovastatin, or rosuvastatin had a lower risk of new-onset 
diabetes (HR 0.45, 0.66, and 0.53 respectively; P,0.0001 
for all), while those receiving pravastatin had a higher risk 
(HR 1.4; P,0.0001). Atorvastatin did show a higher risk 
for new-onset diabetes; however, when adjusted for age, 
sex, use of concomitant medications, and dose, this finding 
was no longer statistically significant (adjusted HR 1.15; 
P=0.5465). Hence, it has a dose-dependent effect on the risk 
of new-onset diabetes. Simvastatin did not increase the risk 
for new-onset diabetes (HR 1.1; P=0.3034), thus it seemed 
to have a neutral effect.39
Drug interactions
The increased risk of myopathy/rhabdomyolysis is a major 
issue that should be considered when using Juvisync with 
other drugs. Table 2 indicates the most important drugs that 
may interact with Juvisync.16,19
Special populations
Precautions should be taken into consideration when using 
Juvisync in special populations. These are summarized in 
Table 3.16,19
FDA-approved indications  
and potential uses
Juvisync (sitagliptin and simvastatin) is approved by the FDA 
for use in patients who require treatment with both sitagliptin 
and simvastatin. Sitagliptin is indicated in adults with type 
2 DM as an adjunct to diet and exercise. Simvastatin is indi-
cated in patients with an increased risk for atherosclerotic 
vascular disease due to hypercholesterolemia. It is used as an 
adjunct to diet when nonpharmacologic measures alone have 
been inadequate. In patients with existing CHD or at high 
risk of CHD, it is indicated with diet to reduce CHD-related 
mortality, risk of nonfatal myocardial infarction and stroke, 
and the need for coronary and noncoronary revascularization 
procedures. It is also indicated in primary hyperlipidemia 
to decrease LDL, total cholesterol, and triglycerides, and 
increase to high-density lipoprotein.16,19
On September 26, 2013, Merck, known as MSD outside 
the United States and Canada, said that the company will 
voluntarily discontinue distributing JUVISYNC™ tablets to 
pharmacies and wholesalers in the United States and Puerto 
Rico. This decision is for business reasons only and is not 
due to the efficacy or safety profile of JUVISYNC™ or the 
individual components. Sitagliptin and simvastatin will con-
tinue to be available as separate medicines. JUVICOR®, the 
brand name of the sitagliptin/simvastatin combination tablet 
outside the United States, will continue to be marketed and 
distributed outside the United States. JUVICOR is currently 
approved in 10 countries, and Merck plans to continue filing 
applications in additional countries.24
Dosage, administration, and cost
The available dosages in Juvisync are 100 mg/10 mg, 
100 mg/20 mg, and 100 mg/40 mg of sitagliptin/simvastatin 
once daily in the evening. The tablets should not be split, 
crushed, or chewed before swallowing.16 The recommended 
starting dose is 100 mg/40 mg per day. If the patient is 
already taking simvastatin, Juvisync is initiated at the 100 
mg dose of sitagliptin and the dose of simvastatin already 
being taken. If used as an adjunct to an insulin secretagogue 
or with insulin, the dose of the latter should be lowered to 
reduce the risk of hypoglycemia. Lipid levels should be 
measured 4 or more weeks after starting or titrating the dose. 
Juvisync is not recommended in patients with moderate or 
severe renal impairment or end-stage renal disease. However, 
Table 2  Drug interactions associated with increased risk of 
myopathy/rhabdomyolysis
Interacting agents Prescribing 
recommendations
Itraconazole, ketoconazole, posaconazole, 
erythromycin, clarithromycin, telithromycin,  
human immunodeficiency virus protease  
inhibitors, nefazodone, gemfibrozil,  
cyclosporine, danazol
Contraindicated  
with Juvisync
Verapamil, diltiazem Do not exceed  
100 mg/10 mg Juvisync daily
Amiodarone, amlodipine, ranolazine Do not exceed  
100 mg/20 mg Juvisync daily
Grapefruit juice Avoid large quantities of 
grapefruit juice (more than 
950 mL daily)
Table 3 Special populations and Juvisync
Special populations Comments
Pediatric (aged ,18 years) Safety and efficacy of Juvisync has not 
been established in this population
Geriatric Considering the higher risk of myopathy 
and renal failure in this population, 
caution is warranted upon using Juvisync
Pregnancy/lactation Use of Juvisync is contraindicated in this 
population
Renal impairment Juvisync is not recommended in 
moderate or severe renal impairment
Hepatic impairment Juvisync is contraindicated in patients 
with active liver disease or persistent 
unexplained elevated liver enzymes
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it can be used in mild renal impairment (serum creatinine 
levels #1.7 mg/dL in men and #1.5 mg/dL in women).16
According to the manufacturer, the cost of Juvisync 
will be the same as the price of Januvia™ (sitagliptin) 
alone, which is $216 for a one-month supply, so it is cost-
effective for patients requiring both medications.40 In addi-
tion, the patent for Juvisync will not end before April 2017, 
hence no generics would be seen until then.
Conclusion
Juvisync should be used in patients requiring both sitaglip-
tin and simvastatin. Sitagliptin was noninferior to glipizide 
as add-on therapy but with lower rates of hypoglycemia 
and weight gain. In addition, although it was inferior to 
insulin, rates of hypoglycemia were significantly lower 
with  sitagliptin. Thus, sitagliptin offers a worthy choice for 
diabetic patients to improve glycemic control with a lower 
risk of hypoglycemia and weight gain. Further, all trials have 
shown cardioprotective benefits of statin use in DM patients 
regardless of baseline lipid levels or existing cardiac disease. 
Both medications have also demonstrated an acceptable 
side effect profile. However, caution is needed when this 
product is coadministered with any drug that may increase 
the level of simvastatin to avoid the risks of myopathy and 
rhabdomyolysis.
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